AstraZeneca is reportedly in talks to move production of its coronavirus vaccine to a Maryland-based factory operated by Catalent, Inc.
the new York Times Reported That the British drugmaker is in talks with the federal government to retrofit a production line after drugmaker Emergent Biosolutions was forced to stop manufacturing the vaccine at a plant in Baltimore.
AstraZeneca wins $1.2 billion contract last May from the federal government for clinical trials and for the production of 300 million doses of the vaccine.
A federal official told The Times that the government was negotiating its contract to move production of the vaccine from Emergent to Catalent.
Catalent currently produces AstraZenca vaccines for export.
AstraZeneca spokeswoman Holly Campbell told The Times: “We can confirm that we are working with Catalent but did not disclose specific details on supplies.” A spokesperson for Catalent declined to comment on the newspaper.
Hill has reached out to AstraZeneca and Catalent for comment.
The move comes after Biden administration removed AstraZeneca from the Emergent plant after a manufacturing accident, while Johnson & Johnson’s one-dose coronavirus vaccine was also being made on site. J&J was given complete control over the camp.
Workers reportedly mixed two ingredients in vaccines, contaminating up to 15 million doses. The facility was manufacturing both vaccines at the time.
The Food and Drug Administration (FDA) halted production of the vaccine at the plant while it inspected the facility. a report from the inspection Multiple failures revealedIncluding not following procedures to prevent cross-contamination.
The Times reported that inspectors conducted another onsite review of the emergency plant on Wednesday.
AstraZeneca’s two-dose vaccine is not yet authorized in the US, but the administration have pledged To donate supplements to countries in need. Earlier this year, several countries temporarily stopped use of the vaccine, acknowledging concerns that it was linked to a rare blood clot.
Disclaimer: The opinions expressed within this article are the personal opinions of the author. The facts and opinions appearing in the article do not reflect the views of knews.uk and knews.uk does not assume any responsibility or liability for the same.